Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Antibody | 1 |
Biosimilar | 1 |
Top 5 Target | Count |
---|---|
RANKL(Tumor necrosis factor ligand superfamily member 11) | 1 |
Target |
Mechanism IL-6RA antagonists |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date15 Sep 2023 |
Target |
Mechanism CSF-3R agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date28 Mar 2022 |
Target |
Mechanism TNF-α inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date02 Apr 2019 |
Start Date05 Mar 2024 |
Sponsor / Collaborator |
Start Date05 Jul 2021 |
Sponsor / Collaborator |
Start Date01 Sep 2020 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Denosumab biosimilar(Fresenius Kabi SwissBioSim GmbH) ( RANKL ) | Osteoporosis, Postmenopausal More | Phase 3 |
Adalimumab biosimilar (Merck Serono Sa) ( TNF-α ) | - | Pending |
Pegfilgrastim biosimilar(Fresenius Kabi) ( CSF-3R ) | - | Pending |
Tocilizumab biosimilar(Fresenius Kabi ) ( IL-6RA ) | - | Pending |